Press releases

ILC Therapeutics, a specialist developer of hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications, announces that it has successfully completed a fundraise of £2.5m.

Scottish biotech ILC Therapeutics has completed its most recent investment round and is on track to commercialise a suite of antiviral medicines for the treatment of respiratory infections including SARS-CoV-2.

Scottish biotech ILC Therapeutics has signed a R&D partnership with international veterinary group Dechra Pharmaceuticals PLC  which will see both entities develop ILC's Caniferon product to treat atopic dermatitis in dogs. Atopic dermatitis is the most common form of eczema affecting

• Drug also has potential to treat SARS, HIV, hepatitis and respiratory infection (RSV)• Earlier research shows drug is 15-20 times more potent than other interferons• Far fewer side effects than current treatments ILC Therapeutics has completed in vivo tests

Pioneering biotech company strengthened by senior appointments to bolster capabilities in research, product development and clinical trials of COVID-19 drug.  Company ready to accelerate the development of Alfacyte™ - ILC's lead hybrid interferon designed to combat viral infections including COVID-19.

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs…

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a new class of interferon drugs…

ILC Therapeutics has welcomed NHS plans to make Covid-19 treatments available to patients as soon as possible.

ILC Therapeutics has secured substantial funding from its first international investor, Medical Incubator Japan (MIJ).

ILC Therapeutics has confirmed that its unique synthetic Interferon called Alfacyte™ is 15 to 20 times more effective at preventing the spread of SARS-CoV-2 Independent research at the University of St Andrews demonstrated the superior effectiveness of Alfacyte™ in vitro

ILC Therapeutics has struck a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.